Beam Therapeutics Inc BEAM

$24.23 -0.04 (-0.16%)

Valuation

Market cap
2,506,800,000
Revenue TTM
$139,740,000
Net income TTM
$-79,990,000
PE ratio
0.00
Forward PE
—
Profit margin
-57.24%
Debt to equity
0.09

Trading

Volume
1,274,300
Avg volume
1,834,234
Day's range
$23.44 – $24.66
Shares out
103,288,000
Stochastic %K
41%
Beta
2.22
Analysts
Strong Sell
Price target
$48.43

Price

Company profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparti...

Show more

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 327 8775
Website
https://beamtx.com
Address
238 Main Street, Cambridge, United States

Latest news

Stocktwits

jewell69 Sep 29, 3:56 AM
$OUST had a bad day today 9/28 -7.58% today Unable 2 re-enter $BEAM at 23.80 ( ordered when it was at 23.90) U.S. Senate passes Save College Sports Act $GLD Gold Rush TV Show. Reality gold mining tv program (usually filmed in Alaska / Yukon ) New Season starts Friday 10/2 8 pm EDT Watching $OUST for possible FIRST time trade
0 replies
Fun11 Sep 28, 4:30 PM
$BEAM where u going
0 replies
jewell69 Sep 28, 2:40 PM
$BEAM 9/28 10:39 am edt trying 2 bi 200 23.81 now offered at .88 No approved drugs today. CAR-T type. Seeking lung drug approval. Stock fell tons around 9/18
0 replies
Bastox Sep 27, 7:13 PM
$BEAM I have to give Stockmoon his due Looks like he may be right about Abbvie
0 replies
None_ Sep 25, 9:03 PM
$CRSP $BEAM $NTLA $PRME $EDIT CRISPR Therapeutics has publicly discussed AI as part of its R&D strategy, whereas I did not find equally clear, company-specific evidence for Beam, Editas, Intellia or Prime Medicine. That does not mean the other companies do not use AI internally. CRISPR is building a broader toolbox. The company has existing nuclease, base-editing, SyNTase, gene-insertion (including site-specific HDR based integration and retrotransposons), and delivery (LNPs intended to retarget delivery to different tissues) programmes. However, the available sources do not establish that it has already reached the same level of demonstrated AI-led discovery as every specialised platform I have been tracking.
3 replies
Andysss Sep 25, 5:20 AM
$BEAM $CRSP $EDIT $NTLA $PRME some shorts may be underestimating the sector. Don’t know if it’s a bot, but a “great example” of how we tend to simplify what we try to interpret. If anything, AI will increase the value of companies that already know how to turn gene-editing biology into actual drugs
1 replies
Bastox Sep 25, 2:09 AM
$BEAM Mega Buy! Bank of America purchased 720,648 Beam Therapeutics shares worth approximately $24.73 million, giving it a 0.70% stake. Institutional investors collectively own 99.68% of the company.
0 replies
None_ Sep 24, 10:12 PM
$CRSP $BEAM $NTLA $PRME $EDIT I think the announcement is relevant to the competitive landscape because it illustrates a potential change in where the bottleneck lies. Historically, researchers often started with a known enzyme class and attempted to improve its properties. AI-enabled mining can instead help identify new combinations that researchers might not have searched systematically. That could benefit different types of platforms, including Basecamp Research, Profluent, Brink Therapeutics, and others. The discovery highlights the value of searching for unusual natural systems. These approaches overlap, but they are not interchangeable. A model that is exceptional at discovering unusual protein families might not be equally effective at optimising an integrase for precise insertion in say in primary human T-cells.
3 replies